Ireland
--:--IST
Recruiting Not applicable

NEUROprotection Via optimizINg Cerebral Blood Flow afTer cArdiaC arresT (NEURO-INTACT) Study

NCT05679739 · tracked via the Priya Life Science Singapore tracker
Phase
Not applicable
Started
2023-08-29
Last updated
2025-05-16

Condition(s) studied

Out-Of-Hospital Cardiac Arrest (OHCA)

Investigational drug(s) / intervention(s)

Individualized blood pressure strategy

Individualized blood pressure strategy: An individualized blood pressure strategy targeting cerebral blood flow, serially guided by near-infrared spectroscopy and transcranial Doppler ultrasound. Assessments are performed on admission, and at 12, 24 and 48 hours post-ROSC.

Study summary

This single-center proof of concept study aims to assess the efficacy of a blood pressure strategy targeting person- and time-specific cerebral blood flow compared with standard-of-care using neuron-specific enolase as a quantitative biomarker of brain injury. Our central hypothesis is that an individualized blood pressure strategy targeting cerebral perfusion will reduce the extent of brain injury as indicated by changes in levels of neuron-specific enolase from baseline at 72 hours. To test this hypothesis, we will recruit 49 patients to an individualized blood pressure management strategy targeting cerebral blood flow, where optimal blood pressure will be serially calculated by the ICM+ brain monitoring software (Cambridge, UK) using inputs from transcranial Doppler ultrasound and near-infrared spectroscopy.

Eligibility

Sex
ALL
Min age
21 Years
Max age
79 Years
Healthy volunteers
No
Inclusion Criteria: 1. At least 21 years of age 2. Comatose defined as not being able to obey verbal commands and no verbal response to pain after sustained ROSC. Exclusion Criteria: 1. ≥ 80 years old at time of enrolment 2. Pregnant patients 3. Limitations of care or life support therapy withdrawn within 24 hours of admission

Primary outcome measure(s)

  • Mean change in neuron-specific enolase (NSE) — 72 hours post ROSC
    The mean change in concentration of NSE from baseline levels to 72 hours post-ROSC.

Trial sites (1)

FacilityCityRegionStatus
National University Heart Centre, Singapore Singapore Singapore Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05679739 on ClinicalTrials.gov ↗ ← All trials in Singapore